ArticleCancer medicine2025
Association Between Area-Level Socioeconomic Disadvantage and Immunotherapy in Patients With Non-Small Cell Lung Cancer.
Article in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundRecent advances in immunotherapy have improved the survival of patients with non-small cell lung cancer (NSCLC). However, data on the association between patient socioeconomic status (SES) and the use of immunotherapy remain scarce. We examined the association between area-level SES and immunotherapy use in patients with stage IV NSCLC in Japan.
methodsData from a national inpatient database were used for this analysis. Patients aged ≥ 18 years, hospitalized for stage IV NSCLC, and treated with immunotherapy alone, immunotherapy combined with platinum-based chemotherapy, and platinum-based chemotherapy alone as first-line pharmacotherapy from April 2016 to March 2022 were analyzed. Area-level SES was measured using the area deprivation index and categorized into quartiles. The primary outcome was the use of immunotherapy as a first-line treatment. A multivariate linear regression model was used, adjusted for patient characteristics, years, and hospital fixed effects.
resultsA total of 47,291 eligible patients from 843 hospitals, with 22,205 (47%) receiving immunotherapy. Adjusted analyses showed that patients in the most disadvantaged area were less likely to receive immunotherapy compared with those in the least disadvantaged area (adjusted difference, -2.0 percentage points [pp]; 95% confidence interval, -3.6 to -0.5 pp; p = 0.01). Although not significant, this trend persisted when stratified by urban and cancer-designated hospitals. However, this difference was no longer significant after adjusting for hospital fixed effects.
conclusionIn Japan, with universal public health insurance with low out-of-pocket costs, living in a socioeconomically disadvantaged area is associated with lower rates of immunotherapy use among patients with stage IV NSCLC. These disparities disappeared within the same hospitals using hospital fixed effects; however, such disparities tended to persist in urban, non-academic, and cancer-designated hospitals. These findings suggest the need for interventions to address the structural barriers, including those within the hospitals, to optimize NSCLC treatment and reduce health disparities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.